

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+5.62%
-2.32%
-3.26%
+11.01%
+11.27%
MNKD
MannKind
$5.49
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Technical Indicators

5+ Days Up
Chart
$5.53 (-0.72%)
$3.86 (+42.23%)
$4.42 (+24.21%)
$7.44 (-26.21%)
MNKD has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

MNKD overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MNKD Analysts opinion is positive and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MNKD Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayMNKD Earnings
The TTM reflects 12-month period, providing review of MNKD financial performance.
The company financial health has moderately improved over the past year
Financial Score
What is MNKD current stock price?
What are MNKD stock strengths?
What risks are associated with MNKD stock?
When is MNKD next earnings report?
What is MNKD market cap and volume?
What is MNKD's current Stock IQ?
Should I buy MNKD stock right now?
Is MNKD a Strong Buy right now?
What does a 'Strong Buy' rating mean for MNKD?
What does a 'Strong Sell' rating mean for MNKD?
What factors influence MNKD's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+5.62%
-2.32%
-3.26%
+11.01%
+11.27%
MNKD
MannKind
Current Price
$5.49
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Technical Indicators

5+ Days Up
Chart
$5.53 (-0.72%)
$3.86 (+42.23%)
$4.42 (+24.21%)
$7.44 (-26.21%)
MNKD Analysts Opinion
MNKD Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
MNKD Analysts opinion is positive and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MNKD Street view is extremely bullish and have positive views on the near-term outlook
MNKD has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels.
MNKD Earnings
The TTM data reflects the most recent 12-month period, providing overview of MNKD financial performance.
MNKD Financial Health
The company financial health has moderately improved over the past year
Financial Score
MNKD Latest Analysis
HC Wainwright & Co. Reiterates MannKind (MNKD) Buy Recommendation. Fintel reports that on October 13 2025 HC Wainwright &. Co. reiterated coverage of MannKind (NasdaqGM:MNKD) with a Buy recommendation. Analyst Price Forecast Suggests 120.96% Upside
Mon Oct 13, 2025
FDA Accepts MannKinds SBLA For Afrezza Assigns PDUFA Target Action Date Of May 29 2026 . (RTTNews) - MannKind Corp. (MNKD) Monday announced that the United States Food and Drug Administration (FDA) has accepted the supplemental biologics license application for Afrezza (insulin human) Inhalation Powder for the treatment of type 1 or type 2 diabetes in children and adults.
Mon Oct 13, 2025
MNKD Crosses Below Key Moving Average Level. In trading on Friday shares of MannKind Corp (Symbol: MNKD) crossed below their 200 day moving average of $4.88 changing hands as low as $4.81 per share. MannKind Corp shares are currently trading off about 5.8% on the day. The chart below shows the one year performance of M
Fri Oct 10, 2025
MannKind Completes Acquisition of scPharmaceuticals Accelerating Revenue Growth in Cardiometabolic Care. DANBURY Conn. and BURLINGTON Mass. Oct. 07 2025 (GLOBE NEWSWIRE) --
Tue Oct 7, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MNKD Stock trends
MNKD Stock performance
MNKD Stock analysis
MNKD investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.